Product Description
JMKX001899, a new potent oral small-molecule KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Its antitumor activity in the intracranial is unclear. (Sourced from: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8630)
Mechanisms of Action: KRAS G12C Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Jemincare
Company Location: Asia Pacific
Company Founding Year: 2011
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07242274 |
JY-JM1899-103 | P3 |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2027-12-31 |
2025-11-22 |
Primary Endpoints|Treatments |
|
NCT06946927 |
JMKX1899-C101 | P1 |
Recruiting |
Non-Small-Cell Lung Cancer |
2026-02-01 |
2025-07-02 |
||
CTR20242061 |
CTR20242061 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-09-14 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20240890 |
CTR20240890 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-08-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20241629 |
CTR20241629 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-06-27 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|